Literature DB >> 19675283

Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.

Ian S Zagon1, Renee N Donahue, Patricia J McLaughlin.   

Abstract

The opioid growth factor (OGF) regulates cell proliferation of human cancer cells through the cyclin-dependent kinase inhibitory pathway, with mediation of this action by the OGF receptor (OGFr). The ubiquity of the OGF-OGFr axis in human cancer is unknown. We used 31 human cancer cell lines, representative of more than 90% of neoplasias occurring in humans, and found that OGF and OGFr were detected in the cytoplasm and nucleus by immunohistochemistry. The addition of OGF to cultures depressed cell number up to 41%, whereas naltrexone (NTX) increased cell proliferation by up to 44%, a total of 85% in the modulating capacity for the OGF-OGFr axis. Neutralization of OGF by specific antibodies led to a marked increase in cell number. Knockdown of OGFr by OGFr-siRNA resulted in a significant increase in the number of cells, even in the face of the addition of exogenous OGF. The cultures to which NTX was added and subjected to OGFr-siRNA were similar to those with OGF-siRNA alone. The OGF-OGFr axis, a physiological determinant of cell-proliferative activity, is a ubiquitous feature of human cancer cells. The identification of this native biological system in neoplasia may be important in understanding the pathophysiology of neoplasia, and in designing treatment modalities that utilize the body's own chemistry.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19675283     DOI: 10.1152/ajpregu.00414.2009

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  27 in total

1.  Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation.

Authors:  Fan Cheng; Patricia J McLaughlin; William A Banks; Ian S Zagon
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-06-30       Impact factor: 3.619

2.  High Level of Fasting Plasma Proenkephalin-A Predicts Deterioration of Kidney Function and Incidence of CKD.

Authors:  Christina-Alexandra Schulz; Anders Christensson; Ulrika Ericson; Peter Almgren; George Hindy; Peter M Nilsson; Joachim Struck; Andreas Bergmann; Olle Melander; Marju Orho-Melander
Journal:  J Am Soc Nephrol       Date:  2016-07-08       Impact factor: 10.121

Review 3.  Opioid growth factor and the treatment of human pancreatic cancer: a review.

Authors:  Ian S Zagon; Patricia J McLaughlin
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

4.  Selective opioid growth factor receptor antagonists based on a stilbene isostere.

Authors:  David P Stockdale; Michelle B Titunick; Jessica M Biegler; Jessie L Reed; Alyssa M Hartung; David F Wiemer; Patricia J McLaughlin; Jeffrey D Neighbors
Journal:  Bioorg Med Chem       Date:  2017-06-27       Impact factor: 3.641

5.  Exogenous OGF enhances the anti-tumor activity of cisplatin on hepatocellular carcinoma.

Authors:  Yinhe Sikong; Qing Wang; Meijuan Cai; Aijun Zhang; Fei Pang; Xiangdan Cui
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

6.  Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment.

Authors:  Moshe Rogosnitzky; Milton J Finegold; Patricia J McLaughlin; Ian S Zagon
Journal:  Invest New Drugs       Date:  2012-12-30       Impact factor: 3.850

7.  Featured Article: Nuclear export of opioid growth factor receptor is CRM1 dependent.

Authors:  Nancy P Kren; Ian S Zagon; Patricia J McLaughlin
Journal:  Exp Biol Med (Maywood)       Date:  2015-09-30

Review 8.  Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures.

Authors:  Karina Liubchenko; Kevin Kordbacheh; Nika Khajehdehi; Tanja Visnjevac; Frederick Ma; James S Khan; Myles Storey; Alaa Abd-Elsayed; Ognjen Visnjevac
Journal:  Adv Ther       Date:  2020-12-18       Impact factor: 3.845

9.  Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays.

Authors:  José María Sayagués; Celia Fontanillo; María del Mar Abad; María González-González; María Eugenia Sarasquete; Maria del Carmen Chillon; Eva Garcia; Oscar Bengoechea; Emilio Fonseca; Marcos Gonzalez-Diaz; Javier De las Rivas; Luís Muñoz-Bellvis; Alberto Orfao
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

10.  Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.

Authors:  Patricia J McLaughlin; Ian S Zagon; Sunny S Park; Andrea Conway; Renee N Donahue; David Goldenberg
Journal:  BMC Cancer       Date:  2009-10-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.